- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | IMMUNOVIA AB: Immunovia announces determined exercise price for warrants series TO 3 | 1 | Cision News | ||
| Mo | Immunovia AB: Immunovia provides further positive data from the VERIFI study of its next-generation pancreatic cancer test | 67 | PR Newswire | LUND, Sweden, March 24, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced additional results... ► Artikel lesen | |
| Mo | Immunovia AB: Immunovia provides further positive data from the VERIFI study of its next-generation pancreatic cancer test | 75 | GlobeNewswire (Europe) | LUND (SWEDEN) - Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced additional results from the successful VERIFI study of its next-generation pancreatic... ► Artikel lesen | |
| 21.03. | IMMUNOVIA AB: Immunovia to host a webcast to share more data from the successful VERIFI clinical validation study | 2 | Cision News | ||
| 19.03. | Immunovia AB: Immunovia announces another successful clinical validation of its next-generation pancreatic cancer test | 71 | GlobeNewswire (Europe) | LUND (SWEDEN) - Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced positive results from the VERIFI study, the second clinical validation study of its next-generation... ► Artikel lesen | |
| 03.03. | IMMUNOVIA AB: Immunovia's CLARITI study results selected for prestigious presentation at the world's largest gastroenterology conference | 1 | Cision News | ||
| IMMUNOVIA Aktie jetzt für 0€ handeln | |||||
| 25.02. | Immunovia reports Q4 results | 2 | Seeking Alpha | ||
| 25.02. | Immunovia AB: Immunovia Publishes Full Year Report for 2024 | 112 | PR Newswire | LUND, Sweden, Feb. 25, 2025 /PRNewswire/ --
October- December 2024
Net sales, which for the quarter only included royalties, amounted to 455 KSEK (155).
... ► Artikel lesen | |
| 21.02. | Immunovia initiates search for a new CFO | 3 | Seeking Alpha | ||
| 21.02. | IMMUNOVIA AB: Immunovia initiates search for a new CFO to support commercialization in the USA | 3 | Cision News | ||
| 21.02. | IMMUNOVIA AB: Invitation to Immunovia's Q4 presentation | 2 | Cision News | ||
| 31.01. | Change in number of shares and votes in Immunovia AB (publ) | 214 | PR Newswire | LUND, Sweden, Jan. 31, 2025 /PRNewswire/ -- During January 2025, the registered number of shares and votes in Immunovia AB (publ) ("Immunovia") has increased due exercise of warrants of series... ► Artikel lesen | |
| 20.01. | Immunovia AB announces outcome of exercise of warrants series TO 2 | 299 | PR Newswire | LUND, Sweden, Jan. 20, 2025 /PRNewswire/ -- The exercise period for warrants series TO 2 (the "Warrant Programme") in Immunovia AB (publ) ("Immunovia" or the "Company") ended on 16 January... ► Artikel lesen | |
| 08.01. | Immunovia AB (Publ) presents Nomination Committee | 203 | PR Newswire | LUND, Sweden, Jan. 8, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced the appointment of the Company's Nomination Committee.... ► Artikel lesen | |
| 02.01. | The exercise period for warrants of series TO 2 beings today: Immunovia AB | 298 | PR Newswire | LUND, Sweden, Jan. 2, 2025 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that today, 2 January 2025, the exercise period for warrants of series TO 2... ► Artikel lesen | |
| 02.01. | IMMUNOVIA AB: The exercise period for warrants of series TO 2 beings today | 2 | Cision News | ||
| 28.12.24 | Immunovia AB: Immunovia announces determined exercise price for warrants series TO 2 and conditionally securing 65% of the warrant programme | 769 | PR Newswire | LUND, Sweden, Dec. 28, 2024 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that the exercise price for warrants series TO 2 (the "warrants") has been... ► Artikel lesen | |
| 20.12.24 | IMMUNOVIA AB: Immunovia discovery study published in top protein research journal | 9 | Cision News | ||
| 19.12.24 | Immunovia AB: End of the Year 2024 Letter from Immunovia CEO Jeff Borcherding | 150 | PR Newswire | LUND, Sweden, Dec. 19, 2024 /PRNewswire/ -- As we near the holidays and year end, I am energized by what Immunovia has accomplished in 2024 and the opportunities... ► Artikel lesen | |
| 18.12.24 | IMMUNOVIA AB: Immunovia CEO and board members announce intention to fully exercise their TO2 warrants | 1 | Cision News |
Seite:
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 7,517 | +0,74 % | Teladoc Health Aktie: Geschäftsjahresende im Blick | Der Telemedizin-Anbieter erweitert sein Angebot durch strategische Kooperationen, während Führungskräfte Anteile veräußern und die Aktie volatil bleibt. Bei Teladoc Health kam es kürzlich zu mehreren... ► Artikel lesen | |
| HIMS & HERS HEALTH | 26,920 | +0,49 % | Smart Money Is Betting Big In HIMS Options | ||
| BECTON DICKINSON | 208,50 | -0,29 % | BD appoints Gregory J. Hayes to its board of directors | ||
| DEXCOM | 62,59 | +0,03 % | Dexcom-Aktie büßt 2,24 Prozent ein (67,4215 €) | Im Minus liegt aktuell die Aktie von Dexcom . Die Aktie notiert derzeit bei 73,00 US-Dollar. Für die Aktie von Dexcom steht gegenwärtig ein Minus von 2,24 Prozent zu Buche. Das Papier verbilligte sich... ► Artikel lesen | |
| INVITAE | - | - | Invitae Aktie: Drastischer Kursverfall trotz Umsatzwachstum | Der Aktienkurs des Biotechnologieunternehmens Invitae ist in den letzten Tagen stark eingebrochen. Am 8. September fiel der Kurs um 25% auf 0,0003 USD, was einen besorgniserregenden Trend fortsetzt.... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,648 | -1,37 % | Atossa-Therapeutics-Direktor Remmel H. Lawrence kauft Aktien für 7.000 US-Dollar | ||
| EVOFEM BIOSCIENCES | - | - | Evofem Signs Sourcing Partnership With Windtree, Expects To Reduce Production Cost Of Phexxi By 60% | ||
| RYMAN HEALTHCARE | 1,440 | -1,10 % | RYMAN HEALTHCARE LIMITED: Ryman finalises repayment of debt facilities | ||
| SONOMA PHARMACEUTICALS | 2,520 | -100,00 % | Sonoma Pharmaceuticals, Inc. - 8-K, Current Report | ||
| CYTOSORBENTS | 0,909 | -2,15 % | Insights into CytoSorbents' Upcoming Earnings | ||
| TEMPEST THERAPEUTICS | 0,726 | +1,18 % | Tempest Therapeutics: Tempest Reports Year End 2024 Financial Results and Provides Business Update | • Granted Both Orphan Drug & Fast Track designations for Amezalpat (TPST-1120) for the treatment of patients with Hepatocellular Carcinoma (HCC)• Announced Agreement with Roche to Support Advancement... ► Artikel lesen | |
| ONTRAK | 1,500 | -11,24 % | Ontrak Health Announces 2024 Third Quarter Financial Results | MIAMI--(BUSINESS WIRE)--Ontrak, Inc. (NASDAQ: OTRK) ("Ontrak" or the "Company"), a leading AI-powered and technology-enabled behavioral healthcare company, today reported its financial results... ► Artikel lesen | |
| SENSEONICS | 0,612 | -2,46 % | Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results | Received FDA approval for Eversense® 365 Continuous Glucose Monitoring system and launched Eversense 365 with commercial partner, Ascensia Patient base increased 56% in 2024 over 2023 to approximately... ► Artikel lesen | |
| PATTERSON COMPANIES | 28,600 | -0,69 % | PATTERSON COMPANIES, INC. - 8-K, Current Report | ||
| STAAR SURGICAL | 16,365 | -0,40 % | STAAR Surgical's 10% owner adds $2.4M worth of stocks |
Das Unternehmen IMMUNOVIA AB kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 0,008 Euro und damit +5,48 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMMUNOVIA AB finden Sie auf Wallstreet Online.
